Diclofenac etalhyaluronate sodium SR is under clinical development by Seikagaku and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Diclofenac etalhyaluronate sodium SR LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diclofenac etalhyaluronate sodium SR overview

Diclofenac Etalhyaluronate Sodium (Joycle) is a non-steroidal anti-inflammatory agent. It is formulated as injectable solution for intra-articular route of administration. Joycle is indicated for the treatment of osteoarthritis (hip joint and knee joint).

Diclofenac etalhyaluronate sodium is under development for the treatment of Tachycardia (Tachyarrhythmias), osteoarthritis (knee,hip and ankle). The drug candidate is administered through intra-articular route. The drug candidate is a formulation of hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) which is chemically bound by using Seikagaku's glycosaminoglycan (GAG) modification technology and drug binding technology. It is a sustained-release formulation. It was also under development for the treatment of enthesopathy which includes lateral epicondylitis and plantar fasciitis.

Seikagaku overview

Seikagaku is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers medicines, medical, oral care, and bulk products through its pharmaceutical division; and endotoxin-detecting reagents through its limulus amebocyte lysate (LAL) business segment. Seikagaku is investigating SI-6603, a condoliase induced drug targeting lumbar disc herniation; SI-613 formulation to treat pain and inflammation associated with osteoarthritis and enthesopathy; SI-614, a modified hyaluronate drug against dry eye; and SI-722, a novel chemical compound targeting interstitial cystitis and bladder pain syndrome. It is also developing SI-449, an anti-adhesion material that prevents post-operative adhesion formation by creating a barrier between the surgical wound site and surrounding tissues. Seikagaku is headquartered in Chiyoda-ku, Tokyo, Japan.

For a complete picture of Diclofenac etalhyaluronate sodium SR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.